AVROBIO (NASDAQ:AVRO) Issues Quarterly Earnings Results, Misses Expectations By $0.10 EPS

AVROBIO (NASDAQ:AVROGet Rating) issued its quarterly earnings results on Tuesday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.10), MarketWatch Earnings reports.

Shares of AVROBIO stock traded down $0.03 during trading on Wednesday, hitting $0.80. 9,979 shares of the stock were exchanged, compared to its average volume of 727,977. The stock has a market capitalization of $34.96 million, a price-to-earnings ratio of -0.28 and a beta of 1.73. The company has a fifty day moving average price of $1.23 and a 200-day moving average price of $2.57. AVROBIO has a 1-year low of $0.78 and a 1-year high of $11.00. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.09.

AVRO has been the topic of several recent research reports. Wedbush lowered their price target on shares of AVROBIO from $14.00 to $4.00 in a research note on Wednesday. Barclays lowered their price target on shares of AVROBIO from $6.00 to $4.00 in a research note on Wednesday. Finally, Zacks Investment Research upgraded shares of AVROBIO from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research note on Monday, March 21st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $6.86.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. grew its stake in AVROBIO by 219.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,381,758 shares of the company’s stock valued at $5,319,000 after buying an additional 949,620 shares during the last quarter. Geode Capital Management LLC grew its stake in AVROBIO by 12.7% in the 4th quarter. Geode Capital Management LLC now owns 650,207 shares of the company’s stock valued at $2,503,000 after buying an additional 73,323 shares during the last quarter. Bank of New York Mellon Corp grew its stake in AVROBIO by 24.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 145,456 shares of the company’s stock valued at $813,000 after buying an additional 28,295 shares during the last quarter. Barclays PLC grew its stake in AVROBIO by 78.2% in the 4th quarter. Barclays PLC now owns 101,106 shares of the company’s stock valued at $389,000 after buying an additional 44,355 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in AVROBIO by 57.2% in the 4th quarter. Wells Fargo & Company MN now owns 91,942 shares of the company’s stock valued at $354,000 after buying an additional 33,447 shares during the last quarter. Institutional investors and hedge funds own 63.92% of the company’s stock.

About AVROBIO (Get Rating)

AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease.

Featured Stories

Earnings History for AVROBIO (NASDAQ:AVRO)

Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.